Imagen de portada del espectáculo Podcasts for Cardiac Researcher and Cardiologists

Podcasts for Cardiac Researcher and Cardiologists

Podcast de Jason Kim

inglés

Tecnología y ciencia

Oferta limitada

2 meses por 1 €

Después 4,99 € / mesCancela cuando quieras.

  • 20 horas de audiolibros / mes
  • Podcasts exclusivos
  • Podcast gratuitos
Empezar

Acerca de Podcasts for Cardiac Researcher and Cardiologists

We present cutting-edge cardiac research. Each episode covers the main arguments and briefly touches on the background. These podcasts are not for beginners but for individuals with extensive knowledge in cardiac research and cellular biology.

Todos los episodios

2 episodios

Portada del episodio Redirected T Cells Target Cardiac Fibrosis

Redirected T Cells Target Cardiac Fibrosis

Aghajanian, H., Kimura, T., Rurik, J.G. et al. Targeting cardiac fibrosis with engineered T cells. Nature 573, 430–433 (2019). https://doi.org/10.1038/s41586-019-1546-z Published: 11 September 2019 by Jonathan A. Epstein [https://www.nature.com/articles/s41586-019-1546-z#auth-Jonathan_A_-Epstein-Aff1-Aff2-Aff3-Aff4] Group at UPenn Abstract: Fibrosis is observed in nearly every form of myocardial disease1 [https://www.nature.com/articles/s41586-019-1546-z#ref-CR1]. Upon injury, cardiac fibroblasts in the heart begin to remodel the myocardium by depositing excess extracellular matrix, resulting in increased stiffness and reduced compliance of the tissue. Excessive cardiac fibrosis is an important factor in the progression of various forms of cardiac disease and heart failure2 [https://www.nature.com/articles/s41586-019-1546-z#ref-CR2]. However, clinical interventions and therapies that target fibrosis remain limited3 [https://www.nature.com/articles/s41586-019-1546-z#ref-CR3]. Here we demonstrate the efficacy of redirected T cell immunotherapy to specifically target pathological cardiac fibrosis in mice. We find that cardiac fibroblasts that express a xenogeneic antigen can be effectively targeted and ablated by adoptive transfer of antigen-specific CD8+ T cells. Through expression analysis of the gene signatures of cardiac fibroblasts obtained from healthy and diseased human hearts, we identify an endogenous target of cardiac fibroblasts—fibroblast activation protein. Adoptive transfer of T cells that express a chimeric antigen receptor against fibroblast activation protein results in a significant reduction in cardiac fibrosis and restoration of function after injury in mice. These results provide proof-of-principle for the development of immunotherapeutic drugs for the treatment of cardiac disease. #CardiacFibrosis #CarT #FAP

9 de may de 2025 - 12 min
Portada del episodio Selective inhibition of stromal mechanosensing suppresses cardiac fibrosis

Selective inhibition of stromal mechanosensing suppresses cardiac fibrosis

Cho, S., Rhee, S., Madl, C.M. et al. Selective inhibition of stromal mechanosensing suppresses cardiac fibrosis. Nature (2025). https://doi.org/10.1038/s41586-025-08945-9 Published: 30 April 2025 from Joseph C. Wu [https://www.nature.com/articles/s41586-025-08945-9#auth-Joseph_C_-Wu-Aff1-Aff2] Group at Stanford University, School of Medicine Abstract: Matrix-derived biophysical cues are known to regulate the activation of fibroblasts and their subsequent transdifferentiation into myofibroblasts, but whether modulation of these signals can suppress fibrosis in intact tissues remains unclear, particularly in the cardiovascular system. Here we demonstrate across multiple scales that inhibition of matrix mechanosensing in persistently activated cardiac fibroblasts potentiates—in concert with soluble regulators of the TGFβ pathway—a robust transcriptomic, morphological and metabolic shift towards quiescence. By conducting a meta-analysis of public human and mouse single-cell sequencing datasets, we identify the focal-adhesion-associated tyrosine kinase SRC as a fibroblast-enriched mechanosensor that can be targeted selectively in stromal cells to mimic the effects of matrix softening in vivo. Pharmacological inhibition of SRC by saracatinib, coupled with TGFβ suppression, induces synergistic repression of key profibrotic gene programs in fibroblasts, characterized by a marked inhibition of the MRTF–SRF pathway, which is not seen after treatment with either drug alone. Importantly, the dual treatment alleviates contractile dysfunction in fibrotic engineered heart tissues and in a mouse model of heart failure. Our findings point to joint inhibition of SRC-mediated stromal mechanosensing and TGFβ signalling as a potential mechanotherapeutic strategy for treating cardiovascular fibrosis. #CardiacFibrosis #CarT #FAP

8 de may de 2025 - 17 min
Regístrate para escuchar
Soy muy de podcasts. Mientras hago la cama, mientras recojo la casa, mientras trabajo… Y en Podimo encuentro podcast que me encantan. De emprendimiento, de salid, de humor… De lo que quiera! Estoy encantada 👍
Soy muy de podcasts. Mientras hago la cama, mientras recojo la casa, mientras trabajo… Y en Podimo encuentro podcast que me encantan. De emprendimiento, de salid, de humor… De lo que quiera! Estoy encantada 👍
MI TOC es feliz, que maravilla. Ordenador, limpio, sugerencias de categorías nuevas a explorar!!!
Me suscribi con los 14 días de prueba para escuchar el Podcast de Misterios Cotidianos, pero al final me quedo mas tiempo porque hacia tiempo que no me reía tanto. Tiene Podcast muy buenos y la aplicación funciona bien.
App ligera, eficiente, encuentras rápido tus podcast favoritos. Diseño sencillo y bonito. me gustó.
contenidos frescos e inteligentes
La App va francamente bien y el precio me parece muy justo para pagar a gente que nos da horas y horas de contenido. Espero poder seguir usándola asiduamente.

Elige tu suscripción

Más populares

Oferta limitada

Premium

20 horas de audiolibros

  • Podcasts exclusivos

  • Disfruta los podcast de Podimo sin anuncios

  • Cancela cuando quieras

2 meses por 1 €
Después 4,99 € / mes

Empezar

Premium Plus

100 horas de audiolibros

  • Podcasts exclusivos

  • Disfruta los podcast de Podimo sin anuncios

  • Cancela cuando quieras

Disfruta 30 días gratis
Después 9,99 € / mes

Prueba gratis

Sólo en Podimo

Audiolibros populares

Preguntas frecuentes

Más preguntas y respuestas
Empezar

2 meses por 1 €. Después 4,99 € / mes. Cancela cuando quieras.